Selective inhibition of spermatogenesis in the presence of normal libido following combined treatment with an LHRH agonist and testosterone in the dog.
In order to maintain libido in dogs treated with an LHRH agonist, animals were administered with testosterone in a gel form for percutaneous adsorption. Histological aspect of testis indicate a complete blockade of spermatogenesis after treatment with the LHRH agonist and the addition of testosterone to these animals did not restore the spermatogenesis. The measurement of testicular steroid levels showed that following LHRH-A administration, the concentration of androgens in testis remained low in the presence or absence of testosterone supplement. However, the prostate weight as well as the volume of ejaculate returned to normal when testosterone was added and this observation can be correlated with the high amount of androgens in prostate. The present study supports the use of LHRH agonist in combination with testosterone as a selective method for inhibition of spermatogenesis in the male.
D000818:Animals; D004285:Dogs; D004359:Drug Therapy, Combination; D012739:Gonadal Steroid Hormones / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000494:pharmacology; D007989:Libido / Q000187:drug effects*; D008297:Male; D009929:Organ Size / Q000187:drug effects; D011467:Prostate / Q000187:drug effects; D013076:Sperm Count; D013091:Spermatogenesis / Q000187:drug effects*; D013737:Testis / Q000187:drug effects; D013739:Testosterone / Q000494:pharmacology*; D017329:Triptorelin Pamoate / Q000031:analogs & derivatives*
D012739:Gonadal Steroid Hormones; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; C019176:Tryptal